WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the final progression free survival (PFS) data from the Phase 2 PRECEDENT clinical trial of EC145 in women with platinum-resistant ovarian cancer will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 3-7 in Chicago, Illinois.
